Arrowhead Pharmaceuticals, INC. (ARWR) — SEC Filings

Overview

Arrowhead Pharmaceuticals, INC. (ARWR) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-K filed on Nov 25, 2025: Arrowhead Pharmaceuticals, Inc. (ARWR) achieved a significant milestone in 2025 with the FDA approval and commercial launch of REDEMPLO (plozasiran) for Familial Chylomicronemia Syndrome (FCS), marking its first commercial product. The company is actively pursuing a supplemental NDA for REDEMPLO in

Sentiment Summary

Across 31 filings, the sentiment breakdown is: 2 bullish, 1 bearish, 28 neutral. The dominant filing sentiment for Arrowhead Pharmaceuticals, INC. is neutral.

Filing Type Overview

Arrowhead Pharmaceuticals, INC. (ARWR) has filed 2 10-K, 12 8-K, 1 10-K/A, 6 10-Q, 2 DEF 14A, 1 SC 13G, 5 SC 13G/A, 1 8-K/A, 1 DEFA14A with the SEC between Jan 2024 to Nov 2025.

Filings by Year

2025 · 2024

Recent Filings (31)

• Arrowhead Launches First Commercial Drug, Eyes sHTG Expansion — 10-K · Nov 25, 2025 Risk: medium
  Arrowhead Pharmaceuticals, Inc. (ARWR) achieved a significant milestone in 2025 with the FDA approval and commercial launch of REDEMPLO (plozasiran) for Familia
• 8-K Filing — 8-K · Nov 18, 2025
• Arrowhead Amends 10-K for Governance Details, No Financial Changes — 10-K/A · Oct 10, 2025 Risk: low
  Arrowhead Pharmaceuticals, Inc. (ARWR) filed a 10-K/A on October 10, 2025, solely to include Part III information (Items 10-14) that was omitted from its origin
• Arrowhead Pharma inks $1.2B deal with Horizon for plozasiran — 8-K · Sep 12, 2025 Risk: medium
  Arrowhead Pharmaceuticals, Inc. (ARWR) announced on September 11, 2025, that it has entered into a collaboration and license agreement with Horizon Therapeutics
• 8-K Filing — 8-K · Sep 11, 2025
• Arrowhead Pharmaceuticals Files 8-K Report — 8-K · Sep 2, 2025 Risk: low
  On September 2, 2025, Arrowhead Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns the entry into a material definitive agreement and the
• Arrowhead's Q3 Loss Widens on Higher R&D, Revenue Declines — 10-Q · Aug 7, 2025 Risk: high
  Arrowhead Pharmaceuticals reported a net loss of $50.3 million for the three months ended June 30, 2025, a significant increase from the net loss of $39.8 milli
• Arrowhead Pharmaceuticals Files 10-Q for Q2 2025 — 10-Q · May 12, 2025 Risk: medium
  Arrowhead Pharmaceuticals, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported its financial results and provided updates on its busi
• Arrowhead Pharma Reports Executive & Director Changes — 8-K · Apr 15, 2025 Risk: medium
  On April 11, 2025, Arrowhead Pharmaceuticals, Inc. reported changes in its executive and director positions. The company announced the departure of certain offi
• Arrowhead Pharmaceuticals Files 8-K — 8-K · Mar 19, 2025 Risk: low
  Arrowhead Pharmaceuticals, Inc. filed an 8-K on March 19, 2025, reporting on matters submitted to a vote of security holders and financial statements as of Marc
• Arrowhead Pharma Files Q4 2024 Report — 10-Q · Feb 10, 2025 Risk: low
  Arrowhead Pharmaceuticals, Inc. filed its quarterly report for the period ended December 31, 2024. The company is registered in Delaware and trades on The Nasda
• Arrowhead Pharma Files 8-K: Board & Executive Compensation Changes — 8-K · Feb 7, 2025 Risk: medium
  Arrowhead Pharmaceuticals, Inc. announced on February 7, 2025, changes in its board of directors and executive compensation. The filing details the departure of
• Arrowhead Pharma Files DEF 14A on Executive Compensation — DEF 14A · Jan 29, 2025 Risk: low
  Arrowhead Pharmaceuticals, Inc. filed a DEF 14A on January 29, 2025, detailing executive compensation and corporate governance matters for the fiscal year endin
• Arrowhead Pharmaceuticals Appoints New Director — 8-K · Dec 18, 2024 Risk: low
  Arrowhead Pharmaceuticals, Inc. announced on December 17, 2024, that its Board of Directors appointed Dr. Christopher M. Marlett as a new director, effective De
• 10-K Filing — 10-K · Nov 26, 2024
• SC 13G Filing — SC 13G · Nov 14, 2024
• SC 13G/A Filing — SC 13G/A · Oct 16, 2024
• Arrowhead Pharmaceuticals Files Q3 2024 10-Q — 10-Q · Aug 8, 2024 Risk: medium
  Arrowhead Pharmaceuticals, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial results and provided updates on its busin
• Arrowhead Pharma Files Q2 2024 10-Q — 10-Q · May 9, 2024 Risk: medium
  Arrowhead Pharmaceuticals, Inc. filed its 10-Q for the period ending March 31, 2024. The company reported its financial results and provided updates on its busi
• SC 13G/A Filing — SC 13G/A · Apr 10, 2024
• Arrowhead Pharmaceuticals Files 8-K — 8-K · Mar 19, 2024 Risk: low
  Arrowhead Pharmaceuticals, Inc. filed an 8-K on March 19, 2024, reporting on matters submitted to a vote of security holders and financial statements. The filin
• Arrowhead Pharma Files 8-K/A Amendment — 8-K/A · Mar 18, 2024 Risk: low
  Arrowhead Pharmaceuticals, Inc. filed an 8-K/A amendment on March 18, 2024, related to events that occurred on February 21, 2024. The filing concerns the depart
• Arrowhead Pharma Files Definitive Additional Proxy Materials — DEFA14A · Feb 27, 2024 Risk: low
  ARROWHEAD PHARMACEUTICALS, INC. filed a DEFA14A on February 27, 2024, as definitive additional materials for a proxy statement. The filing indicates that the co
• Arrowhead Pharma Files 8-K on Officer Compensatory Arrangements — 8-K · Feb 22, 2024 Risk: medium
  Arrowhead Pharmaceuticals, Inc. filed an 8-K on February 22, 2024, reporting an event that occurred on February 21, 2024. The filing pertains to Item 5.02, spec
• Vanguard Group Updates 9.4% Stake in Arrowhead Pharma — SC 13G/A · Feb 13, 2024 Risk: low
  The Vanguard Group, a major investment management company, filed an amended SC 13G/A on February 13, 2024, disclosing its ownership in Arrowhead Pharmaceuticals
• Arrowhead Pharmaceuticals, Inc. Files 10-Q for Period Ending December 31, 2023 — 10-Q · Feb 6, 2024 Risk: medium
  ARROWHEAD PHARMACEUTICALS, INC. (ARWR) filed a Quarterly Report (10-Q) with the SEC on February 6, 2024. Arrowhead Pharmaceuticals, Inc. filed a 10-Q report for
• Arrowhead Pharmaceuticals, Inc. Files Definitive Proxy Statement — DEF 14A · Jan 26, 2024 Risk: low
  ARROWHEAD PHARMACEUTICALS, INC. (ARWR) filed a Proxy Statement (DEF 14A) with the SEC on January 26, 2024. Arrowhead Pharmaceuticals, Inc. filed a Definitive Pr
• State Street Corp Amends Passive Stake in Arrowhead Pharma — SC 13G/A · Jan 24, 2024
  State Street Corp, a major financial institution, filed an amended SC 13G/A on January 24, 2024, disclosing its ownership of Arrowhead Pharmaceuticals Inc. comm
• BlackRock Trims Arrowhead Pharma Stake to 6.6% — SC 13G/A · Jan 23, 2024
  BlackRock Inc. filed an amended SC 13G/A on January 23, 2024, disclosing its ownership in Arrowhead Pharmaceuticals Inc. As of December 31, 2023, BlackRock repo
• Arrowhead Pharma Reports Executive Compensation Changes — 8-K · Jan 22, 2024
  Arrowhead Pharmaceuticals, Inc. filed an 8-K on January 22, 2024, reporting an event that occurred on January 16, 2024. This filing indicates a change in compen
• Arrowhead Pharma Enters Material Definitive Agreement — 8-K · Jan 4, 2024
  Arrowhead Pharmaceuticals, Inc. filed an 8-K on January 4, 2024, reporting an "Entry into a Material Definitive Agreement" as of January 2, 2024. This filing in

Related Companies

ALNY · SRPT · AMGN · TAK · GSK · NVS · TERN · ZBIO

Frequently Asked Questions